1. CMV in the HSCT Recipient

3. Allogenic Stem Cell Transplantation Where Are We?

4. CMV Infections After HSCT

5. Concerns for Increased Risk of CMV Infection

6. Burden of Disease Mortality and Cost

7. Approaches to CMV Preemptive Therapy

8. Approaches to CMV Testing

9. CMV VL Testing Challenges

10. Considerations When Monitoring CMV VL

11. Preemptive Strategies DNA CMV Polymerase Inhibitors

12. Concerns With Prophylaxis

13. Where Have We Made Progress?

14. Maribavir: Treatment Phase 2: Initially Promising

15. Maribavir: Prophylaxis Phase 3: No Difference When Compared With PBO

16. Brincidofovir for CMV Prevention Phase 2

17. Brincidofovir for CMV Prevention Phase 3

18. Letermovir for CMV Prevention Phase 3

19. Letermovir Safety Results

20. Impacts on Practice Use of Letermovir

21. Impacts on Practice Drug-Drug Concerns

22. Moving Forward

23. Concluding Remarks

24. Abbreviations

25. Abbreviations (cont)